<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574197</url>
  </required_header>
  <id_info>
    <org_study_id>9810</org_study_id>
    <nct_id>NCT00574197</nct_id>
  </id_info>
  <brief_title>Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients</brief_title>
  <official_title>Assessment of Gastrointestinal Tolerability and Efficacy of Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of
      mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of
      transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of
      Cellcept®. The new enteric-coated, Myfortic® is presently FDA approved for the prevention of
      acute kidney rejection only. There is no clinical data of its use in heart transplant
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-labeled, prospective, non-randomized pilot-phase study of the enteric-coated,
      Myfortic® versus the non enteric-coated, Cellcept® in patients who are within 5 years of
      having undergone heart transplant surgery who are currently taking Cellcept®. After the
      initial screening, 20 patients who fulfill the inclusion criteria and report symptoms of
      gastrointestinal side-effects while taking Cellcept will be switched to Myfortic. All 20
      patients will be followed closely over a period of 6 months following enrollment. Concomitant
      immunosuppressive therapy will continue in all patients per standard treatment protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI Tolerability as Measured by GSRS</measure>
    <time_frame>6 month</time_frame>
    <description>Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale)
GSRS has 15 items, each rated on a 7-point scale from 1 (no discomfort) to 7 (very severe discomfort). GSRS total minimum value is 15; maximum value is 105. Higher scores represent greater discomfort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Efficacy as Measured by Incidence of Rejection Episodes, Graft Loss and Outcome.</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of biopsy proven acute rejection, graft loss, and death due to rejection.
Number of rejection episodes where rejection is defined as Grade 1B or higher on myocardial biopsy as measured by the 1990 Grading System of the International Society of Heart and Lung Transplantation for Acute Cellular Rejection. Grading system has:
grade 0 (no acute rejection)
grade 1A (Focal, mild acute rejection)
grade 1B (Diffuse, mild acute rejection)
grade 2 (Focal, moderate acute rejection)
grade 3A (multifocal moderate rejection)
grade 3B (Diffuse, borderline severe acute rejection)
grade 4 (Severe acute rejection).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Gastrointestinal Symptoms</condition>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Enteric-coated Mycophenolate Sodium (Myfortic)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Sodium</intervention_name>
    <description>1440mg/day (720mg by mouth, twice a day)</description>
    <arm_group_label>Enteric-coated Mycophenolate Sodium (Myfortic)</arm_group_label>
    <other_name>Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of either sex aged 18 and above who have undergone successful orthotopic
             heart transplant surgery.

          2. Patients who are currently taking Cellcept® and experiencing gastrointestinal
             side-effects from this standard therapy.

          3. Individuals on Cellcept® with total dosage of 2 mg a day or less would be eligible to
             participate.

          4. Patients who are able to give written informed consent.

        Exclusion Criteria:

          1. Patients with an absolute neutrophil count &lt;1500 cells/mm3, and/or leukocytopenia
             (&lt;2500 cells/mm3), thrombocytopenia (&lt;75,000 cells/mm3) and significant anemia
             (hemoglobin &lt; 6g/dl) at the time of potential enrollment.

          2. Women of childbearing potential not using the contraception method(s), as well as
             women who are breastfeeding.

          3. Known sensitivity to the study drug or class of the study drug.

          4. Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study.

          5. Use of any other investigational agent in the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst Schwarz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars- Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <results_first_submitted>June 21, 2020</results_first_submitted>
  <results_first_submitted_qc>June 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2020</results_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Lawrence Czer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Heart Transplant</keyword>
  <keyword>gastrointestinal</keyword>
  <keyword>Cellcept</keyword>
  <keyword>Myfortic</keyword>
  <keyword>GI</keyword>
  <keyword>GI symptoms with Mycophenolate Mofetil post heart transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enteric-coated Mycophenolate Sodium (Myfortic)</title>
          <description>1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enteric-coated Mycophenolate Sodium (Myfortic)</title>
          <description>1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GI Tolerability as Measured by GSRS</title>
        <description>Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale)
GSRS has 15 items, each rated on a 7-point scale from 1 (no discomfort) to 7 (very severe discomfort). GSRS total minimum value is 15; maximum value is 105. Higher scores represent greater discomfort.</description>
        <time_frame>6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteric-coated Mycophenolate Sodium (Myfortic)</title>
            <description>1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>GI Tolerability as Measured by GSRS</title>
          <description>Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale)
GSRS has 15 items, each rated on a 7-point scale from 1 (no discomfort) to 7 (very severe discomfort). GSRS total minimum value is 15; maximum value is 105. Higher scores represent greater discomfort.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSRS at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.67" spread="15.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSRS at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.17" spread="19.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Efficacy as Measured by Incidence of Rejection Episodes, Graft Loss and Outcome.</title>
        <description>Incidence of biopsy proven acute rejection, graft loss, and death due to rejection.
Number of rejection episodes where rejection is defined as Grade 1B or higher on myocardial biopsy as measured by the 1990 Grading System of the International Society of Heart and Lung Transplantation for Acute Cellular Rejection. Grading system has:
grade 0 (no acute rejection)
grade 1A (Focal, mild acute rejection)
grade 1B (Diffuse, mild acute rejection)
grade 2 (Focal, moderate acute rejection)
grade 3A (multifocal moderate rejection)
grade 3B (Diffuse, borderline severe acute rejection)
grade 4 (Severe acute rejection).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteric-coated Mycophenolate Sodium (Myfortic)</title>
            <description>1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Efficacy as Measured by Incidence of Rejection Episodes, Graft Loss and Outcome.</title>
          <description>Incidence of biopsy proven acute rejection, graft loss, and death due to rejection.
Number of rejection episodes where rejection is defined as Grade 1B or higher on myocardial biopsy as measured by the 1990 Grading System of the International Society of Heart and Lung Transplantation for Acute Cellular Rejection. Grading system has:
grade 0 (no acute rejection)
grade 1A (Focal, mild acute rejection)
grade 1B (Diffuse, mild acute rejection)
grade 2 (Focal, moderate acute rejection)
grade 3A (multifocal moderate rejection)
grade 3B (Diffuse, borderline severe acute rejection)
grade 4 (Severe acute rejection).</description>
          <units>myocardial biopsies</units>
          <param>Count of Units</param>
          <units_analyzed>myocardial biopsies</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>myocardial biopsies</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No rejection (Grade 0 or 1A)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rejection (Grade 1B or higher)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death due to rejection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enteric-coated Mycophenolate Sodium (Myfortic)</title>
          <description>Enteric-coated Mycophenolate Sodium (Myfortic)
1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Heart re-transplant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypovolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>GI Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Steroid induced myopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a small sample size study and 3 participants did not finish the 6 month visit</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ernst Schwarz, MD, PhD</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>(310) 840-7089</phone>
      <email>Ernst.Schwarz@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

